SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3496-3499. Prepublished online as a Blood First Edition Paper on December 27, 2006; DOI 10.1182/blood-2006-07-036012. This Article Full Text (PDF) All Versions of this Article: blood-2006-07-036012v1 109/8/3496    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Picard, S. Articles by Mahon, F.-X. Search for Related Content PubMed PubMed Citation Articles by Picard, S. Articles by Mahon, F.-X. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 20, 2006 Accepted December 6, 2006 Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud, Nicholas Moore, Mathieu Molimard, and Francois-Xavier Mahon* Department of Clinical Pharmacology and Toxicology, CHU de Bordeaux, University Victor Segalen Bordeaux, INSERM U657, Bordeaux, France Department of Hematology, the Institut Bergonie, Regional Cancer Center, Bordeaux, France Department of Hematology and Blood Diseases, CHU de Bordeaux, University Victor Segalen Bordeaux, INSERM E217, Bordeaux, France * Corresponding author; email: francois-xavier.mahon{at}umr5540.u-bordeaux2.fr. Using high-performance liquid chromatography-tandem mass spectrometry, we assessed trough imatinib plasma levels in 68 chronic myeloid leukemia (CML) patients who responded or not to standard-dose imatinib, after at least 12 months' treatment. Mean trough imatinib plasma levels were significantly higher in the group with complete cytogenetic response (56 patients) than in the group without (12 patients; P = .03) and higher in the group with major molecular response (MMR) than in the group without (34 patients [1452±649 ng/ml] versus 34 patients [869±427 ng/ml]; P < .0001). Regarding trough imatinib plasma levels and their discrimination potential for MMR, the area under receiver-operating characteristic curve was 0.775, with best sensitivity (77%) and specificity (71%) at a plasma threshold of 1002 ng/ml. Therefore, monitoring of imatinib plasma levels could be very useful for the management of CML patients, or should at least be checked in the case of treatment failure or suboptimal response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Therapeutic drug monitoring in CML patients on imatinib Carolyn Blasdel, Merrill J. Egorin, Theodore F. Lagattuta, Brian J. Druker, and Michael W. Deininger Blood 2007 110: 1699-1701. [Full Text] [PDF] Use of therapeutic drug monitoring in CML patients on imatinib François-Xavier Mahon, Stéphane Picard, Gerald Marit, Philip Robinson, and Mathieu Molimard Blood 2007 110: 1701. [Full Text] [PDF] This article has been cited by other articles: J. L. Snead, T. O'Hare, L. T. Adrian, C. A. Eide, T. Lange, B. J. Druker, and M. W. Deininger Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis Blood, October 15, 2009; 114(16): 3459 - 3463. [Abstract] [Full Text] [PDF] D. H. Kim, L. Sriharsha, W. Xu, S. Kamel-Reid, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4750 - 4758. [Abstract] [Full Text] [PDF] G. D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C. D. Blanke, H. Joensuu, and M. von Mehren Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors J. Clin. Oncol., July 1, 2009; 27(19): 3141 - 3147. [Abstract] [Full Text] [PDF] L. Noens, M.-A. van Lierde, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman, P. Martiat, P. Mineur, K. Van Eygen, K. MacDonald, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Blood, May 28, 2009; 113(22): 5401 - 5411. [Abstract] [Full Text] [PDF] M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood, May 7, 2009; 113(19): 4497 - 4504. [Abstract] [Full Text] [PDF] T. W. Kim, M.-H. Ryu, H. Lee, S. J. Sym, J.-L. Lee, H. M. Chang, Y. S. Park, K. H. Lee, W. K. Kang, D. B. Shin, et al. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Oncologist, May 1, 2009; 14(5): 540 - 547. [Abstract] [Full Text] [PDF] F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party Blood, April 9, 2009; 113(15): 3428 - 3434. [Abstract] [Full Text] [PDF] E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF] D. Bixby and M. Talpaz Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2009; 2009(1): 395 - 401. [Abstract] [Full Text] [PDF] M. C. Heinrich, S. George, S. Bauer, and J. A. Fletcher Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies ASCO Educational Book, January 1, 2009; 2009(1): 694 - 699. [Abstract] [Full Text] [PDF] D. L White, V. A Saunders, P. Dang, A. Frede, L. Eadie, S. Soverini, F. Quarantelli, P. Lin, M. Thornquist, D.-W. Kim, et al. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3187 - 3187. [Abstract] T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy Blood, November 15, 2008; 112(10): 3965 - 3973. [Abstract] [Full Text] [PDF] A. Petain, D. Kattygnarath, J. Azard, E. Chatelut, C. Delbaldo, B. Geoerger, M. Barrois, S. Seronie-Vivien, A. LeCesne, G. Vassal, et al. Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults Clin. Cancer Res., November 1, 2008; 14(21): 7102 - 7109. [Abstract] [Full Text] [PDF] S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, and F.-X. Mahon Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, September 1, 2008; 112(5): 2024 - 2027. [Abstract] [Full Text] [PDF] R. A. Larson, B. J. Druker, F. Guilhot, S. G. O'Brien, G. J. Riviere, T. Krahnke, I. Gathmann, Y. Wang, and for the IRIS (International Randomized Interferon Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood, April 15, 2008; 111(8): 4022 - 4028. [Abstract] [Full Text] [PDF] S. D Baker Pharmacokinetic Considerations for Molecularly Targeted Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 705 - 709. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] M. W. Deininger Milestones and Monitoring in Patients with CML Treated with Imatinib Hematology, January 1, 2008; 2008(1): 419 - 426. [Abstract] [Full Text] [PDF] J. E. Cortes Imatinib and Beyond--Therapy of CML in 2008 ASCO Educational Book, January 1, 2008; 2008(1): 307 - 312. [Abstract] [Full Text] [PDF] G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF] C. Blasdel, M. J. Egorin, T. F. Lagattuta, B. J. Druker, and M. W. Deininger Therapeutic drug monitoring in CML patients on imatinib Blood, September 1, 2007; 110(5): 1699 - 1701. [Full Text] [PDF] F.-X. Mahon, S. Picard, G. Marit, P. Robinson, and M. Molimard Use of therapeutic drug monitoring in CML patients on imatinib Blood, September 1, 2007; 110(5): 1701 - 1701. [Full Text] [PDF] A. Sparreboom Unexplored Pharmacokinetic Opportunities with Microdosing in Oncology Clin. Cancer Res., July 15, 2007; 13(14): 4033 - 4034. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020